GSK sets sights on brain diseases through Oxford partnership
Diseases of the brain and central nervous system have been notoriously challenging to treat, even for the world's largest and most well-resourced drug companies.
But...
From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment
Continue readingAdvertisement
Advertisement
Advertisement
Advertisement
Advertisement